OREGON HEALTH & SCIENCE UNIVERSITY;Celator Pharmaceuticals Inc.
发明人:
Max GORDON,Paul TARDI,Jeffrey TYNER,Lawrence MAYER
申请号：
US15774978
公开号：
US20180327854A1
申请日:
2016.11.10
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
